- Home
- PCVX
PCVX
Vaxcyte Inc.
as 04-25-2025 4:00pm EST
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 9.6B | IPO Year: | 2020 |
| Target Price: | $136.50 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.66 - $121.06 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vaxcyte Inc. (PCVX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Mar 5 '25 | Sell | $71.27 | 5,000 | $353,699.01 | 41,620 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Feb 27 '25 | Sell | $73.45 | 8,000 | $586,165.11 | 157,016 | |
| GUGGENHIME ANDREW | PCVX | PRESIDENT AND CFO | Feb 18 '25 | Sell | $84.11 | 8,000 | $670,822.74 | 109,491 | |
| Eydelman Mikhail | PCVX | SVP, GEN COUNSEL & CORP SEC | Feb 5 '25 | Sell | $89.91 | 5,000 | $450,368.64 | 41,620 | |
| Wassil Jim | PCVX | CHIEF OPERATING OFFICER | Feb 3 '25 | Sell | $86.87 | 8,000 | $689,790.43 | 157,016 |
Latest Vaxcyte Inc. News
PCVX Breaking Stock News: Dive into PCVX Ticker-Specific Updates for Smart Investing
Simply Wall St.
11 days ago
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Insider Monkey
16 days ago
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential
Zacks
17 days ago
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
TipRanks
a month ago
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI
TipRanks
a month ago
Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
Zacks
a month ago
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
Clinical Trials Arena
a month ago
Vaxcyte stock sinks despite Phase II IPD vaccine trial success
Investor's Business Daily
a month ago
Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'
Compare PCVX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PCVX Vaxcyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.